By leveraging our proprietary antibody R&D platforms, we have developed a differentiated pipeline, including an approved product and multiple clinical-stage or preclinical drug candidates.
Our core product, Bejescin® (MIL62), is a novel 3rd-generation anti-CD20 monoclonal antibody and has been approved by NMPA for marketing in China for the treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD) and Primary Membranous Nephropathy (PMN). It is the first domestic drug approved for the NMOSD indication in China, as well as the world’s first drug granted approval for the pMN indication.
We strategically focus on the development of antibodies that stimulate the immune system to deplete target pathogenic cells, including three mechanisms: redirecting NK cells to kill target cells, redirecting T cells to kill target cells and infusing multi-specific antibody with immune stimulation activity. For this purpose, we have built proprietary antibody technology platforms, encompassing the process from antibody discovery to development. This enable us to design, evaluate, select and develop optimal drug candidates in an efficient and effective manner.
ADCC-enhanced Antibody Platform
Enhance NK-cell function through antibody glycosylation modification
Multi-specific Antibody Platform
Biology function-driven and structurally design
Antibody Discovery and Optimization Platform
Screen for candidates with high efficiency and low toxicity
Half-Life Extended Antibody Platform
Optimizing the Pharmacokinetic Properties of Antibody Drugs
CMC and Manufacturing Platform
Screen and construct candidate drugs with high expression and stability
